Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy plus DCF neoadjuvant therapy for esophageal cancer
jRCT1061240036Active, not recruiting
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in esophageal cancer. Primary endpoint: Perioperative complications within 30 days after surgery. Started Oct 2024; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1061240036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061240036.